OnTarget: ONgoing Telmisartan Alone
and in combination with Ramipril Global Endpoint Trial: A large,
simple randomized trial of an Angiotensin II Receptor Antagonist
(Telmisartan) and an ACE-Inhibitor (Ramipril) in patients at high
risk for cardiovascular events
Transcend: Telmisartan Randomized AssessmeNt Study in aCE iNtolerant
subjects with cardiovascular Disease |
| |
|
People with coronary artery disease,
poor circulation in the legs, stroke, TIA, or diabetes with
complications are at increased risk of suffering from further
heart attacks, strokes, heart failure or death from these conditions.
Ramipril, an ACE-Inhibitor, has been shown useful at reducing
the risk of these events in this population. Telmisartan, an
angiotensin II antagonist (AIIA), may be just as effective
as ramipril but may have fewer side effects. Further, there
is a possibility that ramipril and telmisartan given in combination
may be more effective in reducing the risk of these events
than either drug alone. Additionally, it has been shown that
AIIAs like telmisartan may delay the onset of diabetes. |
| |
|
The primary aim of ONTARGET is to compare telmisrtan alone,
ramipril alone, and telmistran and ramipril in combination,
for prospective incidence of CVD events in a population at
high risk for such events. High risk individuals unable to
take ramipril because of side effects are directed to the parallel
study, TRANSCEND, which uses an identical treatment protocol
and outcome measures as OnTarget, but in which randomization
is to telmistran or placebo. |
| |
|
ONTARGET has enrolled approximately 28,400 participants from
700 to 800 clinical sites worldwide. Of the 28,400 participants,
23,400 are enrolled in ONTARGET and 5,000 are enrolled in TRANSCEND.
About 5,000 of the participants (4,000 for ONTARGET, 1,000
for TRANSCEND) come from sites in the U.S. A DNA substudy includes
approximately 12,000 participants. |
